Search Results for: Pharma: Clinical Roundup
-
Conatus Pharma Seeks $69M for Liver Drug Emricasan
Meanwhile, Gary Burgess, senior vice president of clinical research and chief medical officer, joined Conatus in 2011 from Pfizer, where he oversaw the assimilation of Idun, including data integration, clinical oversight of ongoing Phase II studies, development of clinical plans and registration strategies for emricasan...In all, emricasan has completed nine clinical studies, including some at Pfizer, enrolling more than 500 participants, according to Conatus -
Akebia's $41M Cash Infusion Boosts Anemia Drug Work
Autifony Therapeutics Ltd., of London, said Pfizer Venture Investments, the venture capital arm of Pfizer Inc., of New York, invested £5 million (US$7.7 million) to join existing investors SV Life Sciences, Imperial Innovations plc and UCL Business plc in its Series A financing round...The financing is expected to fund the lead program to clinical proof of concept for at least one hearing disorder indication. (See BioWorld Today, Aug. 23, 2011 -
ASCO Roundup
Data from an ongoing Phase I/II study confirmed clinical evidence of the antitumor activity at multiple dose levels in patients with anaplastic lymphoma kinase-positive NSCLC, including brain metastases, and initial clinical evidence of antitumor activity in patients with EGFR receptor mutation NSCLC. (See BioWorld Today, Dec. 17, 2012...and the clinical benefit response rate was 82 percent -
Prosensa Leads More Biotechs into IPO Parade
Evoke, a specialty pharma developing a nasal spray formulation of gastrointestinal (GI) drug metoclopramide, is seeking a more modest $23 million and plans to list on Nasdaq as "EVOK...Earlier this year, the Alabama Supreme Court ruled that Pfizer Inc., which acquired Wyeth, is on the hook for injuries caused even by generic versions of Reglan if it failed to warn about risks associated with the drug's long-term use...Since we're not going to have clinical data at the time we would expect the IPO – we -
IPOpalooza Continues with Portola's $122M Offering
GW Pharma plc (NASDAQ:GWPH) commenced trading on May 1, pricing at $8.90, and closed at $8.88 Wednesday...And Lyon, France-based Erytech Pharma SA commenced trading in Paris at €11.60 per share, raising €16.7 million (US$21.4 million) for the company...The company's platform technology is designed to improve drug delivery into internal body cavities. -
Ambit Cuts Price, Ups Shares; $65M IPO to Fund Quizartinib
Despite losing a potentially lucrative FLT3 inhibitor partnership with Astellas Pharma Inc...The company, which originally started out in 1998 and was acquired by Pfizer Inc...Proceeds would be used to fund clinical trials, R&D for additional alpha-1 antitrypsin (AAT) indications, expanding distribution capabilities for additional territories -
Pharma: Clinic Roundup
The study, dubbed Gammaglobulin Alzheimer's Partnership, was conducted in collaboration with the Alzheimer's Disease Cooperative Study, a clinical trial consortium supported by the National Institute on Aging...Bristol-Myers Squibb Co., of New York, and Pfizer Inc., also of New York, said results from a prespecified subanalysis of the ARISTOTLE trial were published in Circulation, showing that the reductions in stroke or systemic embolism, number of major bleeding events and mortality demonstrated -
Clinic Roundup
Secondary objectives of the trial include clinical activity by serum TTR levels...For the Uceris 9-mg group, 17.4 percent of patients achieved clinical and endoscopic remission, compared to 4.5 percent of the placebo group (p = 0.0047...Virobay Inc., of Menlo Park, Calif., and Leo Pharma A/S, of Ballerup, Denmark, achieved a milestone in their collaboration on development of an oral therapy for psoriasis upon initiation of a Phase I trial of VBY-891 by Virobay -
Pharma: Clinic Roundup
Pfizer Inc., of New York, said the REMINDER trial of Inspra (eplerenone) showed statistically significant risk reductions in the primary composite efficacy endpoint, defined as time to first event of cardiovascular mortality, re-hospitalization or extended initial hospital stay due to diagnosis of heart failure (HF), sustained ventricular tachycardia or fibrillation, ejection fraction (EF) BioWorld Today | Tuesday, March 12, 2013
Clinic Roundup
Acceleron Pharma Inc., of Cambridge, Mass., said it started a Phase II study testing dalantercept (ACE-041), an angiogenesis inhibitor designed to target the activin receptor-like kinase pathway, in combination with Inlyta (axitinib, Pfizer Inc.), a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with metastatic renal cell carcinoma
HC Royalty Inks Hefty Deals to Propel Nuron and Raptor
that included a $30 million equity investment and a $50 million synthetic royalty agreement linked to future sales of Meningitec, a vaccine Nuron acquired earlier this month from Pfizer Inc., and its HibTiter vaccine (Haemophilus b conjugate vaccine [diphtheria CRM197 protein conjugate]), in-licensed from Wyeth LLC and subsequently out-licensed in January to Mitsubishi Tanabe Pharma Corp., of Osaka, Japan. (See BioWorld Today, Jan. 13, 2012.) In a second biotech deal on the same day, HC Royalty
Clinic Roundup
TransTech Pharma Inc., of High Point, N.C., said data from a 399-patient study testing TTP488, a small-molecule drug targeting the receptor for advanced glycation endproducts, demonstrated evidence of slowing cognitive decline over 18 months in patients with mild to moderate Alzheimer's disease...The study was sponsored by New York-based Pfizer Inc
Cat on a Hot Twin Proof? After Cougar, Puma Roars
The clinical relevance of neratinib as a 'pan-HER' family inhibitor and it being irreversible is yet to be proven," the paper said...Funds will be used to support the clinical development of cancer drugs aldoxorubicin and tamibarotene and for general corporate purposes, which could include working capital, capital expenditures, R&D and commercial activities.
Pharma: Clinic Roundup
Bristol-Myers Squibb Co., of New York, and Pfizer Inc., also of New York, reported that the reductions in stroke or systemic embolism, major bleeding and mortality demonstrated with Eliquis (apixaban) compared to warfarin in the ARISTOTLE trial were consistent across a wide range of stroke and bleeding risk scores in patients with nonvalvular atrial fibrillation...The company said those findings supported the general safety of routine vaccine with HPV4 in a clinical care setting to prevent cervical
Vascular Pharma Makes Splash: Raises $16M, Inks Janssen Deal
Vascular Pharma will receive an up-front payment and milestone payments in exchange for the acquisition rights...Vascular Pharma expects its funding to last through completion of Phase II, getting the company to the point where Janssen may exercise its option...Pharma giants Boehringer Ingelheim GmbH, of Ingelheim, Germany, and Eli Lilly and Co., of Indianapolis, have thrown their hats into the ring, as well
Pressure Mounts to Mend Holes in PDUFA Package
The request echoes that of the American Society of Clinical Oncologists, which called last week for Congress to put some teeth into the drug shortage reporting requirement. (See BioWorld Today, June 5, 2012.) The conference committee is still hopeful that the House and Senate bills can be reconciled and passed by July 4...We feel it is essential that it be understood that this case could potentially adversely impact ours and other industries whose activities are far removed from the clinical
ASCO 2012 Roundup
Antisense Pharma GmbH, of Regensburg, Germany presented complete data from its Phase I/II study of trabedersen, an antisense compound that specifically inhibits expression of transforming growth factor beta 2 (TGF-β2) – a protein which is overexpressed in advanced tumors – in patients with advanced pancreatic cancer, malignant melanoma or colorectal cancer...CytRx Corp., of Los Angeles, reported Phase Ib/II data showing that tumor-targeting doxorubicin conjugate INNO-206 produced a clinical benefit
Everything Gilead Is Coming Up Gold
Three smashing clinical successes by Gilead Sciences Inc.'s nuc drug GS-7977 for hepatitis C virus (HCV) have lit up the 2012 International Liver Congress of the European Association for the Study of the Liver, sending the company's stock up 12 percent Thursday...Novartis AG put its antiviral DEB025 on clinical hold following reports of pancreatitis
Stemline Therapeutics Follows Verastem's Lead, Files for IPO
In Phase I/II studies, both candidates demonstrated clinical activity, including durable complete responses and an overall survival (OS) benefit...The cancer stem cell space is increasingly busy, with efforts from biotechs and big pharmas, including Astellas Pharma Inc., Sanofi SA, GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Pfizer Inc., OncoMed Pharmaceuticals Inc., Verastem and others
Satori Raises $15M for AD Platform, Looks to File IND
Serendipitously, independent clinical studies of the antecedent biomarkers of AD seem to have corroborated Satori's approach, he added...Despite the huge number of failures, small and large pharma companies have been pouring billions of dollars into the development of molecules that leave a lot to be desired...The company also has an exclusive distribution agreement with Uman Pharma Inc., of Quebec, to commercialize gemcitabine in the U.S. The compound went off patent last year in the U.S